ABSTRACT It is known that the opioid peptide dynorphin A has a broad distribution throughout the neuraxis. Recent biochemical studies have extended the sequence of dynorphin A by 15 amino acids to include another [Leu]enkephalin-containing peptide known as dynorphin B. These sequence data.have been validated by the elucidation of the structure of the hypothalamic mRNA coding for a-and (-neo-endorphin, dynorphin A, and dynorphin B. Using specific antisera directed against each of the three opioid peptides, we have studied their cellular distribution in rat brain. Their distribution patterns are extremely similar, if not identical. Furthermore, all three peptide immunoreactivities can be localized to the same cells in five nuclear groups throughout the brainstem--the. supraoptic nucleus, the paraventricular nucleus, a group of cells in the lateral hypothalamic area, the nucleus parabrachialis, and the nucleus tractus solitarius. The sequence of a common precursor for dynorphin A, B, and a-and f-neo- (16, 17) . Such discrepancies have been attributed either to differential processing ofthe precursor or to different precursors.
viously undescribed peptide sequences not containing enkephalin structures.
Although the-evidence. is conclusive regarding a common precursor for the three [Leu] enkephalin-containing peptides in hypothalamus, there is little biosynthetic information about these peptides in other brain regions. It is reasonable to expect a similar biosynthetic route for dynorphin A in the various known positive cell groups (15) . However, this is by no means self-evident. For example, a-melanotropin-like immunoreactivity can be seen in two cell groups, one being (3-endorphin- positive and the other not (16, 17) . Such discrepancies have been attributed either to differential processing ofthe precursor or to different precursors.
In this paper we present immunocytochemical evidence that a-neo-endorphin, dynorphin A, and dynorphin B immunoreactivities occur within the same cells of several hypothalamic and caudal brainstem nuclei. These findings lead to the conclusion that pro-dynorphin (or a similar precursor) is found. in many different cell types across brain and most likely is the source of the three peptides in various neuronal systems.
The [Leu] enkephalin-containing opioid peptide dynorphin was extracted from pituitary and its sequence was determined (1, 2) ; later, the same was done for dynorphin from gut (3). Immunocytochemical. studies in brain and pituitary (4) localized dynorphin-like immunoreactivity to the vasopressin-producing cells (5) of the magnocellular, neurosecretory neurons of the hypothalamus (supraoptic and paraventricular nuclei) and, the posterior lobe of the pituitary. An identical set of anatomical observations (6-8) was made for a-second [Leujenkephalin-containing opioid peptide, a-neo-endorphin. Further biochemical studies on dynorphin and a-neo-endorphin (9-11) revealed an. extensive distribution throughout the central nervous system. Recently, the sequence beyond position 17 ofdynorphin was extended 15 residues (12) . That region contains Lys-Arg (as residues 18 and 1.9) followed by a 13-residue [Leu]enkephalin-containing-peptide with the following structure: (H)Tyr-Gly-GlyPhe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr(OH) [indepen.-dently confirmed by Kilpatrick et aL (13) ]. This peptide was named dynorphin B., and the original 17-residue dynorphin was renamed dynorphin A (12) . The relationship between these three [Leu]enkephalin-containing opioid peptides has recently been explained by the mRNA sequence elucidated by Kakidani et aL (14) by using cloning methods for cDNA. Using poly(A)-rich mRNA extracted from pig hypothalamus, these workers showed that the, pro-dynorphin precursor produces a-neo-endorphin, dynorphin A, and dynorphin B as well as various pre-
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MATERIALS AND METHODS
Male. Sprague-Dawley. rats were injected by the intracerebroventricular route with 400 ,g of colchicine 48 hr prior to sacrifice, perfused with 4% formaldehyde, and prepared for immunocytochemistry as described (4) . Serial 5-.m sections were.
cut on a cryostat at -20°C through several levels of the hypothalamus, locus ceruleus,. and nucleus tractus solitarius. The tissue was processed by the peroxidase-antiperoxidase method for immunocytochemical study as described (4) . Antisera against dynorphin-A (R-1), dynorphin B (13S), and a-neo-endorphin (#58) were used for immunocytochemical staining at 1:500 dilution for 48 hr; Antiserum R-1 was raised against dynorphin A coupled. to thyroglobulin via glutaraldehyde, as described for antiserum "Lucia" directed toward dynorphin-(1-13). (9) . R-1 exhibits properties indistinguishable from.those of "Lucia" under radioimmunoassay conditions.. Antiserum 13S was raised in a rabbit by the same coupling method except that dynorphin B was the coupled peptide. In radioimmunoassay studies it crossreacted <106 with dynorphin A or [Leu]enkephalin. Antiserum #58 against a-neo-endorphin was also. produced by coupling the peptide to thyroglobulin via glutaraldehyde. The crossreactivities under immunocytochemical conditions for all three antisera are indicated below. Each antiserum was shown to be specific for its original peptide antigen and was blocked by that peptide at 10 ,uM but not by the other two at 50 ,uM or by /3,-endorphin, [Met] enkephalin, [Leu] enkephalin, [Met] enkephalin-Arg6-Gly7-Leu8, [Met] enkephalin-Arg6-Phe7, peptide E, or BAM-22P at 50 ,uM (18) (19) (20) (21) ..
In each of the brain regions studied, adjacent sections were (Fig. 3) . The presence of the three types of immunoreactivity (dynorphin A, dynorphin B, and a-neo-endorphin) in magnocellular and nonmagnocellular nuclei suggests at least two discrete neuronal sources in the -hypothalamus for pro-dynorphin peptides.
In the more caudal brainstem areas-i.e., nucleus parabrachialis and nucleus tractus solitarius-the three antisera also stained the same cell population (Figs. 4 .: \A.. *%.. aration of these-two cell groups from each other and from the three hypothalamic cell groups suggests the broad use of prodynorphin throughout the neuraxis as a source for these three peptides.
DISCUSSION
The results of this study strongly support the common biosynthetic origin of dynorphin A, dynorphin B, and a-neo-endorphin at several levels in the central nervous system. Still, in light of the great anatomical and biochemical complexity of opioid peptide systems, the three known precursors for these peptides, and the heavy reuse ofthe Tyr-Gly-Gly-Phe-Leu (or Met) peptide structures, we searched for areas in which one of the three peptides (dynorphin A, dynorphin B, or a-neo-endorphin) might occur without the other two. No example ofstaining by one antiserum, without similar staining by the other two was found, thereby suggesting consistent biosynthesis of all three peptides from pro-dynorphin. However, a broader search throughout nervous tissue is needed to confirm this impression.
Although the antisera used in this work appear to be specific for the peptide sequences under study, it is not possible to determine the form of immunoreactivity seen under immunohistochemical conditions. Thus, it is unclear whether free peptide, biosynthetic intermediate, or precursor is responsible for the staining. It is certainly conceivable that different neuronal groups may process the pro-dynorphin precursor differentially (22) and that our antisera do not permit us to detect this differential processing. However, it is also apparent that either the pro-hormone or the products of the pro-dynorphin precursor are produced in sufficient amounts to allow the visualization of the three types of immunoreactivity in all five cell groups. It thus is most likely that dynorphin A, dynorphin B, and a-neoendorphin have a common biosynthetic origin both in the endocrine hypothalamic magnocellular-neural lobe system and in the remaining neuronal groups throughout the brain.
It is now clear that there are three families ofopioid peptides in the central nervous system-si) the f&endorphin/corticotropin family with a single opioid peptide and three repeated Fig. 1 (14) . The brain ,-endorphin system consists primarily of a hypothalamic arcuate cell group with long limbic projections (24, 25) , but'the two other families exhibit an extensive distribution with multiple cell groups from spinal cord to cortex (26) . The current information .on the genetic origin of these systems and their general anatomical distribution should lay the groundwork for investigating the local circuitry, the post-translational processing, and the potential functions ofthese opioid peptide families in the central nervous system.
